Syncom Formulations India Reports Strong Q1 FY27 Results

Profit After Tax: ₹24.85 crore (up 58% YoY)
Total Income: ₹133.36 crore (up 8% YoY)

Reader Takeaway: Robust profit growth driven by efficiency; dividend payout proposed.

What just happened

Syncom Formulations (India) Limited announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27). The company posted a consolidated profit after tax (PAT) of ₹24.85 crore, marking a significant 58% increase compared to ₹15.75 crore in the same period last year. Total income for the quarter rose by 8% to ₹133.36 crore from ₹122.94 crore in Q1 FY26.

Why this matters

The substantial profit growth, outpacing revenue expansion, indicates improved operational efficiencies and cost management. This strong performance is a positive signal for shareholders, reflecting the company's ability to translate sales into higher profits. The recommended final dividend also provides a direct return to investors.

The backstory

The company attributes its consistent performance to a long-standing business model focused on ethical, prescription-led marketing. Syncom Formulations operates six specialized divisions with a large field force and focuses on key therapeutic areas. Its manufacturing facility in Pithampur, Madhya Pradesh, supports both domestic and export markets.

What changes now

Shareholders will look forward to the Annual General Meeting (AGM) for the final approval of the recommended dividend of ₹0.10 per equity share. The company's focus on its core prescription-led segments is expected to continue driving growth.

Risks to watch

While the current results are strong, continued execution of the ethical marketing strategy and navigating competitive pressures in the pharmaceutical sector will be crucial for sustained growth.

Peer comparison

Syncom Formulations operates in the pharmaceutical sector. Its performance in profitability and revenue growth in Q1 FY27 will be a key benchmark against its peers as financial results are released.

Context metrics (time-bound)

For Q1 FY27, Syncom Formulations reported revenue from operations of ₹125.53 crore, a 7% increase from ₹116.90 crore in Q1 FY26. Profit before tax grew by 59% to ₹32.25 crore. Earnings Per Share (EPS) stood at ₹0.26, a 53% jump from ₹0.17.

What to track next

Investors should closely follow the company's performance in upcoming quarters, monitor the dividend approval process, and observe any new product launches or market expansions.